Breakfast Briefing Series, October 19, 2018

Are You Deal Ready?

Through the Lens of the Buyer and Investor

Speakers: Fran Brown, Phd, SVP Integrated Drug Development and Business Operations, Certara
Date/Time: October 19, 2018 8:00-10:00 AM (PST), presentation begins at 8:30 sharp
Place: Genentech, Building 42 Room 1C
          475 East Grand Avenue
          South San Francisco, 94080  


Pricing: Free, but online registration is required by October 16th, 2018.


The critical questions that all Biotech companies need to be able to answer is “How does a prospective buyer, partner or investor look at my program and what do I need to do in order to optimize the probability of a successful deal”?  The successful search for a buyer/partner/investor is only partly dependent on the intrinsic properties of the product you are developing. Multiple extrinsic factors can be just as, or more, important than the product itself and in many assessments the decision not to invest is driven by factors over which you have control.

The primary focus of due diligence is to look at risk, risk mitigation and probability of success. This presentation will represent the scientific evaluation side of a deal team’s perspective and will show you the process, as seen through the lens used by due diligence experts that advise VC investors, in-licensing parties and partner deal makers. This session will provide you insights that could immediately be used in your development programs and could improve your readiness for deal and investment engagements.

Speaker Bio: Fran Brown, PhD
Dr. Fran Brown joined Certara Strategic Consulting in 2017 and is currently the SVP Integrated Drug Development and Business Operations in Certara’s Strategic Consulting Division. She is a highly respected professional with proven leadership skills and 25 years of broad experience within pharmaceutical development and due diligence. She has extensive experience with strategic and operational global drug development from early discovery to filing and post-marketing, acquired through working in multiple geographical locations including UK, Switzerland, Canada, Sweden and the USA. Fran possesses a broad knowledge of strategic drug discovery and development, with a special focus on development strategy and the application of Model Informed Drug Development.

After obtaining a degree in pharmacy and a subsequent PhD in pharmacokinetics, Fran started her professional life in the clinical pharmacology department at Hoffman-La Roche progressing to various broader roles including clinical leader, project leader, and research and licensing liaison. Following a rich career at Roche, Fran joined Biovitrum (a Swedish biotech company) as Director of Clinical Operations. In 2010, Fran founded her own consultancy business with an emphasis on using her scientific, pharmacology and development experience to support small companies on the development pathway.

Register here:

*Note: ID required for check-in on event day

Click HERE to view presentation slides.